Evidence map›Paper›PMID 30792653›Full record

ArticleFrontiers in pharmacology2019

Anti-thrombosis Effects and Mechanisms by Xueshuantong Capsule Under Different Flow Conditions.

Shuxian Han, Ying Chen, Jinyu Wang, Qian Zhang, Bing Han, Yimeng Ge, Yanhua Xiang, Rixin Liang, Xiaoxin Zhu, Yun You and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Shuxian HanInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Ying ChenInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Jinyu WangInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Qian ZhangInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Bing HanHarbin Zhenbao Pharmaceutical Co., Ltd., Harbin, China.
Yimeng GeHarbin Zhenbao Pharmaceutical Co., Ltd., Harbin, China.
Yanhua XiangHarbin Zhenbao Pharmaceutical Co., Ltd., Harbin, China.
Rixin LiangInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Xiaoxin ZhuInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Yun YouInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Fulong LiaoInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNHarbin Electric Corporation (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Xueshuantong capsule (XST) is a patented traditional Chinese medicine used for the prevention and treatment of thrombosis. The molecular mechanism of anti-thrombotic effect of XST was investigated through the cross-talk among the platelets/leukocytes, endothelial cells (ECs), and flow shear stress. The Bioflux 1000 system was used to generate two levels of shear stress conditions: 0.1 and 0.9 Pa. Bioflux Metamorph microscopic imaging system was used to analyze the adhesion cell numbers. Protein expressions were detected by western blotting and flow cytometry. The flow-cytometry results showed that under 0.1 Pa flow, XST decreased ADP induced platelets CD62p surface expression in a concentration-dependent manner. Under 0.9 Pa flow, XST at a concentration of 0.15 g⋅L

Indexed as

endothelial cellsinflammationshear stressthrombosisXueshuantong capsule

Identifiers

PMID30792653
PMCPMC6374556
OpenAlexW2911638273

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.